IRB: IRB00130996
Purpose of Study: Recruitment is underway in Baltimore for a research study of pioglitazone (a.k.a. Actos) for inclusion body myositis (IBM). This research is being done to find out if the drug pioglitazone will affect mitochondria in the muscle of IBM patients. We will also determine if pioglitazone is safe in people who have IBM.
Eligibility Criteria:
Study volunteers must meet the following criteria:- Age ≥ 50
- Have a diagnosis of sporadic inclusion body myositis
- Able to walk at least 20 feet, with or without the use of an assistive device
- Able to rise from a chair without support from another person or device
- No history of diabetes mellitus or prior or concurrent treatment with any diabetes therapy
- Willing to come in for 6 on-site visits over 12 months
- Willing to undergo 3 needle muscle biopsies
- Additional criteria apply and will be reviewed with the study team
Study Status:
Recruiting
Principal Investigator:
Jemima Albayda, MD
Assistant Professor of Medicine
Dr. Albayda's research involves harnessing muscle ultrasound for the evaluation of inflammatory muscle disease. Together with collaborators from the Applied Physics Lab, she is pioneering work applying machine intelligence to ultrasound interpretation in order to decrease the subjectivity and allow for automated tools. She is also involved in multimodal collaborative studies with Radiology, and works with other investigators in the Division of Rheumatology to provide an imaging assessment for their studies. She is the principal investigator for an investigator-initiated trial for Pioglitazone in Inclusion Body Myositis.
